Gender differences in hepatitis C seroprevalence and suboptimal vaccination and hepatology services uptake amongst substance misusers

Journal of Medical Virology

Volumn 84, Issue 11, 2012, Pages 1737-1743

  Marufu, Muchandidemba ^a   Williams, Hugh ^b   Hill, Samuel L ^c   Tibble, Jeremy ^a   Verma, Sumita ^a,c  

^a Worthing Hospital   (United Kingdom)

^b SUSSEX PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

^c BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

Hepatitis B vaccination; Hepatitis B virus; Hepatitis C virus; Injecting drug use; Substance misuse service

Indexed keywords

BIOLOGICAL MARKER; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS C ANTIBODY;

ADULT; ANTIBODY DETECTION; ARTICLE; BLOOD ANALYSIS; DRINKING BEHAVIOR; DRUG MISUSE; FEMALE; HEALTH SERVICE; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PROSPECTIVE STUDY; SEROPREVALENCE; SEX DIFFERENCE; VACCINATION;

ADULT; DRUG USERS; ENGLAND; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PROSPECTIVE STUDIES; SEROEPIDEMIOLOGIC STUDIES; SEX FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; VACCINATION;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 84866515637     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23389     Document Type: Article

References (28)

1. Bock HL, Löscher T, Scheiermann N, Baumgarten R, Wiese M, Dutz W, Sanger R, Clemens R. 1995. Accelerated schedule for hepatitis B immunization. J Travel Med 2: 213-217.
2. Extent and causes of international variations in drug usage. 2010. A report for the secretary of State for Health by Professor Sir Mike Richards CBE Secretary. Accessed at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_117962.
3. Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O. 2007. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. Scand J Gastroenterol 42: 247-523.
4. Freidman SR, Curtis R, Neagius A, Jose B, Des Jarlais DC. 1999. Social networks, drug injectors' lives, and HIV/AIDS. New York, NY: Kluwer/Plenum.
5. Graham D, McClean H. Yorkshire Multi-District Clinical Audit Group. 2007. Yorkshire regional audit of hepatitis B vaccination. Int J STD AIDS 18: 212-214.
6. Hagan H, Des Jarlais DC, Stern R, Lelutiu-Weinberger C, Scheinmann R, Strauss S, Flom PL. 2007. HCV synthesis project: Preliminary analyses of HCV prevalence in relation to age and duration of injection. Int J Drug Policy 18: 341-351.
7. Health Protection. Hepatitis C in the UK. 2011 report. Accessed at: http://www.hpa.org.uk/Publications/InfectiousDiseases/BloodBorneInfections/1107 HepCi.
8. Health Protection Agency. Data tables of the unlinked anonymous monitoring survey of HIV and hepatitis in injecting drug. July 2011. Accessed at: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1309969861526ntheUK2011report/.
9. Hickman M, Higgins V, Hope V, Bellis M, Tilling K, Walker A, Henry J. 2004. Injecting drug users in Brighton, Liverpool, and London: Best estimates of prevalence and coverage of public health indicators. J Epidemiol Community Health 58: 766-771.
10. Hope VD, Ncube F, Hickman M, Judd A, Parry JV. 2007. Hepatitis B vaccine uptake among injecting drug users in England 1998 to 2004: Is the prison vaccination programme driving recent improvements? J Viral Hepat 14: 653-660.
11. Hope VD, Hickman M, Ngui SL, Jones S, Telfer M, Bizzarri M, Ncube F, Parry JB. 2011. Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. J Viral Hepat 18: 262-270.
12. Hope V, Parry JV, Marongui A, Ncube F. 2012. Hepatitis C infection among recent initiates to injecting in England 2000-2008: Is a national hepatitis C action plan making a difference? J Viral Hepat 19: 55-64.
13. Irving WL, Smith S, Cater R, Pugh S, Neal KR, Coupland CA, Ryder SD, Thomson BJ, Pringle M, Bicknell M, Hippisley-Cox J. 2006. Clinical pathways for patients with newly diagnosed hepatitis C-What actually happens. J Viral Hepat 13: 264-271.
14. Jack K, Willot S, manners J, Varnam MA, Thomson BJ. 2009. Clinical trial: A primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C. Aliment Pharmacol Ther 29: 38-45.
15. Jeffrey JP, MacQuillan G, Chua F, Galhenage S, Bull J, Young E, Hulse G, O'Neil G. 2007. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatology 45: 111-117.
16. Lettmeier B, Mühlberger N, Schwarzer R, Sroczynski G, Wright D, Zeuzem S, Siebert U. 2008. Market uptake of new antiviral drugs for the treatment of hepatitis C. J Hepatol 49: 528-536.
17. Lewis H, Ibrahim N, Mirza M, Hothi J, Wilkinson M, Foster GR. 2011. Actively injecting drug users can be successfully treated with antiviral therapy for HCV, are unlikely to be re-infected, and significantly reduce their illicit drug use. Hepatology 54: 846A.
18. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. 2000. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132: 296-305.
19. Lum PJ, Ochoa KC, Hahn JA, Page Shafer K, Evans JL, Moss AR. UFO Study. 2003. Hepatitis B virus immunization among young injection drug users in San Franciso, Calif: The UFO study. Am J Public Health 93: 919-923.
20. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. 2011. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modelling analysis of its prevention utility. Hepatol 54: 1137-1144.
21. Nyamathi A, Sinha K, Greengold B, Cohen A, Marfisee M. 2010. Predictors of HAV/HBV vaccination completion among methadone maintenance clients. Res Nurs Health 33: 120-132.
22. Pradat P, Voirin N, Tillmann HL, Chevallier M, Trépo C. 2007. Progression to cirrhosis in hepatitis C patients: An age-dependent process. Liver Int 27: 335-339.
23. Rising Curve. Chronic hepatitis B infection in the UK. 2007. Accessed at: http://www.hepb.org.uk/information/resources/rising curve chronic hepatitis b infection in the uk.
24. Sheard L, Tompkins C. 2008. Contradictions and misperceptions: An exploration of injecting practice, cleanliness, risk, and partnership in the lives of women drug users. Qual Health Res 18: 1536-1547.
25. Sweeting MJ, Hope VD, Hickman M, Parry JV, Ncube F, Ramsay ME, De Angelis D. 2009. Hepatitis C infection among injecting drug users in England and Wales (1992-2006): There and back again. Am J Epidemiol 170: 352-360.
26. The National Plan for Liver Services UK. 2009. Accessed at: http://www.bsg.org.uk/sections/liver-news/the-national-plan-for-liver-services-uk-2009.
27. Sylvestre DL, Clements BJ. 2007. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 19: 741-747.
28. Topp L, Day C, Dore GJ, Maher L. 2009. Poor criterion validity of self-reported hepatitis B infection and vaccination status among injecting drug users: A review. Drug Alcohol Rev 28: 669-675.